The ASCO Post

Founded in 2010, The ASCO Post collaborates with the American Society of Clinical Oncology (ASCO) to share vital information about evidence-based cancer care with a wide range of oncology experts and ASCO members. The ASCO Post is available both in print and online. Each edition highlights reliable reports on clinical cancer research, updates on policies, patient care topics, issues in clinical practice, and insightful opinions from prominent figures in the field of clinical oncology.

National, Trade/B2B

English

Newspaper

Outlet metrics

Domain Authority

Ranking

Global

#428873

United States

#237540

Health/Health Conditions and Concerns

#625

Traffic sources

Monthly visitors

Articles

ROS1-Positive NSCLC: Activity of ROS1 TKI

6 days ago | ascopost.com | Matthew Stenger

In a pooled analysis of the phase II TRUST-I and TRUST-II trials reported in the Journal of Clinical Oncology, Pérol et al found that the oral, potent, CNS-active, selective, next-generation ROS1 tyrosine kinase inhibitor (TKI) taletrectinib was highly active in ROS1-positive advanced or metastatic non–small cell lung cancer (NSCLC). Study DetailsTRUST-I was a Chinese study with two cohorts: TKI-naive patients and patients in whom previous crizotinib failed.
Activity of ROS1 TKI in NSCLC

6 days ago | ascopost.com | Matthew Stenger

In a pooled analysis of the phase II TRUST-I and TRUST-II trials reported in the Journal of Clinical Oncology, Pérol et al found that the oral, potent, CNS-active, selective, next-generation ROS1 tyrosine kinase inhibitor (TKI) taletrectinib was highly active in ROS1-positive advanced or metastatic non–small cell lung cancer (NSCLC). Study DetailsTRUST-I was a Chinese study with two cohorts: TKI-naive patients and patients in whom previous crizotinib failed.
Advanced Esophageal Cancer: NOTCH1 Mutation and Efficacy of Tislelizumab

1 week ago | ascopost.com | Matthew Stenger

In an analysis from the phase III RATIONALE-302 trial reported in the Journal of Clinical Oncology, Lu et al found that the presence of NOTCH1 mutation was associated with improved overall survival in patients receiving second-line tislelizumab vs investigator’s choice of chemotherapy for advanced or metastatic esophageal squamous cell carcinoma.
Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer

1 week ago | ascopost.com | Matthew Stenger

In the French phase II PANACHE01-PRODIGE48 trial, researchers found that neoadjuvant chemotherapy with mFOLFIRINOX (modified leucovorin, fluorouracil, irinotecan, and oxaliplatin) was feasible and active in patients with resectable pancreatic adenocarcinoma. Schwarz et al published these findings in the Journal of Clinical Oncology.
Pediatric ALL or Lymphoblastic Lymphoma: Reduced Induction Dexamethasone and High-Dose Methotrexate

1 week ago | ascopost.com | Matthew Stenger

In a UK phase III trial (UKALL 2011) reported in the Journal of Clinical Oncology, Kirkwood et al found that a shorter duration of induction dexamethasone did not reduce steroid-related toxicity and that high-dose methotrexate (HDM) did not reduce central nervous system (CNS) relapse among patients younger than age 25 with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma.
Ideal Apixaban Dose for Cancer-Associated VTE

1 week ago | ascopost.com | Matthew Stenger

In the API-CAT trial—results of which were reported in The New England Journal of Medicine—Mahé et al found that use of reduced-dose apixaban was noninferior to full-dose apixaban in preventing recurrent venous thromboembolism (VTE) in patients with active cancer.
Metastatic Castration-Resistant Prostate Cancer: Immune-Modulating ADC Targeting CD46

1 week ago | ascopost.com | Matthew Stenger

In a phase I study reported in the Journal of Clinical Oncology, Aggarwal et al reported activity with the antibody-drug conjugate (ADC) FOR46 in patients with metastatic castration-resistant prostate cancer.
Invitation to Colonoscopy vs Fecal Immunochemical Test Screening for Colorectal Cancer

2 weeks ago | ascopost.com | Matthew Stenger

In a Spanish study (COLONPREV) reported in The Lancet, Castells et al found that invitation to fecal immunochemical test (FIT) vs colonoscopy screening for colorectal cancer was associated with noninferiority in colorectal cancer mortality. Study DetailsIn the multicenter study, eligible individuals from across Spain were randomly assigned to invitation to one-time colonoscopy screening (n = 26,332 in intention-to-screen group) or biennial FIT screening (n = 26,719 in intention-to-screen group).
Rescue Therapy for Newly Diagnosed High-Grade Osteosarcoma

2 weeks ago | ascopost.com | Matthew Stenger

In a Japanese trial (JCOG0905) reported in the Journal of Clinical Oncology, Hiraga et al found no disease-free survival benefit with the addition of a higher dose of ifosfamide to methotrexate, doxorubicin, and cisplatin (MAP) in patients with newly diagnosed high-grade osteosarcoma with poor response to preoperative chemotherapy.
Talazoparib Plus Enzalutamide in Advanced Prostate Cancer: Patient-Reported Outcomes

2 weeks ago | ascopost.com | Matthew Stenger

In an analysis from the phase III TALAPRO-2 trial reported in The Lancet Oncology, Matsubara et al found that first-line talazoparib plus enzalutamide was associated with prolonged time to definitive deterioration in global health status/quality of life (GHS/QOL) vs placebo plus enzalutamide in patients with metastatic castration-resistant prostate cancer.